{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:54:51Z","timestamp":1793660091073,"version":"4.5.1"},"reference-count":44,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T00:00:00Z","timestamp":1593302400000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Co., Ltd.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,6,3]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>X-linked hypophosphataemic rickets\/osteomalacia (XLH) is a chronic, debilitating genetic disease characterised by skeletal abnormalities and growth disorder. The burden of XLH begins in childhood and continues throughout life. Conventional medical therapy with phosphate, active vitamin D and surgery do not address the underlying pathophysiology of the disease. While treatment during childhood may improve bone deformity and growth retardation, a large proportion of adult patients still fail to reach normal stature. Furthermore, adult patients with XLH report comorbidities associated with unresolved childhood disease, as well as newly developed disease-related complications and significantly impaired quality of life (QOL). Despite the multiple negative aspects of XLH, Asian consensus statements for diagnosis and management are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The Study of longitUdinal observatioN For patients with X-Linked hypOphosphataemic rickets\/osteomalacia in collaboration With Asian partnERs study is a longitudinal observational cohort study of patients with XLH, designed to determine the medical characteristics and burdens (physical, emotional and financial) of this progressive disease and to evaluate the impact of treatment (including the use of burosumab) on clinical outcomes. The study was initiated in April 2018, and registration will remain open until 30 April 2022. The sample size planned for analyses is 160 patients, consisting of 100 patients in Japan and 60 patients in Korea. Up to 5 years of observation are planned per patient, from enrolment through to April 2023. Prospective and retrospective data will be collected to evaluate variables, including height\/growth, rickets severity score, QOL, motor function and biomarkers for phosphate metabolism and bone turnover.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was obtained from the Ethics Committee of Osaka University, the Ethics Committee of Kyowa Kirin Co and by the Ethics Committee of each participating medical institution. Two interim analyses and associated publications are planned using retrospective and enrolment data at year 1 and results at year 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT03745521\">NCT03745521<\/jats:ext-link>\n                      ; UMIN000031605.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-036367","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T02:15:49Z","timestamp":1593483349000},"page":"e036367","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03745521","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-4405","authenticated-orcid":false,"given":"Takuo","family":"Kubota","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Osaka University, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Il","family":"Cheong","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Seoul National University Children's Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Michigami","sequence":"additional","affiliation":[{"name":"Department of Bone and Mineral Research, Osaka Women's and Children's Hospital, Izumi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Perinatology, Faculty of Medicine, Tottori University, Tottori, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Kyowa Kirin Co Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Kyowa Kirin Co Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Osaka University, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"2025120619125041000_10.6.e036367.1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"key":"2025120619125041000_10.6.e036367.2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0818"},{"key":"2025120619125041000_10.6.e036367.3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(64)90085-3"},{"key":"2025120619125041000_10.6.e036367.4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.10.3615"},{"key":"2025120619125041000_10.6.e036367.5","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.340"},{"key":"2025120619125041000_10.6.e036367.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1014-8","article-title":"Fgf23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2025120619125041000_10.6.e036367.7","doi-asserted-by":"publisher","DOI":"10.1007\/BF02185769"},{"key":"2025120619125041000_10.6.e036367.8","doi-asserted-by":"publisher","DOI":"10.1002\/1098-1004(200007)16:1<1::AID-HUMU1>3.0.CO;2-J"},{"key":"2025120619125041000_10.6.e036367.9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.pcl.2018.09.004","article-title":"Hypophosphatemic rickets","volume":"66","author":"Bitzan","year":"2019","journal-title":"Pediatr Clin North Am"},{"key":"2025120619125041000_10.6.e036367.10","first-page":"88","article-title":"Genetic causes of rickets","volume":"9","author":"Acar","year":"2017","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2025120619125041000_10.6.e036367.11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021105"},{"key":"2025120619125041000_10.6.e036367.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020881"},{"key":"2025120619125041000_10.6.e036367.13","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukarGeneExpr.v22.i1.50"},{"key":"2025120619125041000_10.6.e036367.14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"2025120619125041000_10.6.e036367.15","doi-asserted-by":"publisher","DOI":"10.1530\/EC-13-0103"},{"key":"2025120619125041000_10.6.e036367.16","unstructured":"Tenenhouse HS , Econs MJ . Mendelian hypophosphatemias. In: Scriver CR , Beaudet AL , Sly WS , et al , eds. The metabolic and molecular basis of inherited disease. 8 edn. New York: McGraw Hill, 2000: 5039\u201367."},{"key":"2025120619125041000_10.6.e036367.17","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0661"},{"key":"2025120619125041000_10.6.e036367.18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"2025120619125041000_10.6.e036367.19","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-211961","article-title":"Chiari malformation, syringomyelia and bulbar palsy in X linked hypophosphataemia","volume":"2015","author":"Watts","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2025120619125041000_10.6.e036367.20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-2522"},{"key":"2025120619125041000_10.6.e036367.21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/jbmr.3614","article-title":"High incidence of cranial synostosis and chiari I malformation in children with X-linked hypophosphatemic rickets (XLHR)","volume":"34","author":"Rothenbuhler","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2025120619125041000_10.6.e036367.22","doi-asserted-by":"crossref","first-page":"153892","DOI":"10.1016\/j.metabol.2019.03.009","article-title":"Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH)","volume":"103S","author":"Rothenbuhler","year":"2020","journal-title":"Metabolism"},{"key":"2025120619125041000_10.6.e036367.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-012-2364-9"},{"key":"2025120619125041000_10.6.e036367.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-010-1705-9"},{"key":"2025120619125041000_10.6.e036367.25","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2015-2199"},{"key":"2025120619125041000_10.6.e036367.26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00467-011-2046-z","article-title":"Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment","volume":"27","author":"Quinlan","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"2025120619125041000_10.6.e036367.27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1507\/endocrj.EJ15-0289","article-title":"Pathogenesis and diagnostic criteria for rickets and osteomalacia - proposal by an expert panel supported by ministry of health, labour and welfare, Japan, the Japanese society for bone and mineral research and the Japan endocrine society [Opinion]","volume":"62","author":"Fukumoto","year":"2015","journal-title":"Endocr J"},{"key":"2025120619125041000_10.6.e036367.28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025120619125041000_10.6.e036367.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.02.014"},{"key":"2025120619125041000_10.6.e036367.30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00774-015-0698-7","article-title":"Pathogenesis and diagnostic criteria for rickets and osteomalacia--proposal by an expert panel supported by the ministry of health, labour and welfare, Japan, the Japanese Society for bone and mineral research, and the Japan endocrine Society","volume":"33","author":"Fukumoto","year":"2015","journal-title":"J Bone Miner Metab"},{"key":"2025120619125041000_10.6.e036367.31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bone.2019.02.010","article-title":"Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic rickets severity score","volume":"122","author":"Thacher","year":"2019","journal-title":"Bone"},{"key":"2025120619125041000_10.6.e036367.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.284.6329.1607"},{"key":"2025120619125041000_10.6.e036367.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1991.tb01616.x"},{"key":"2025120619125041000_10.6.e036367.34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0022034517728497","article-title":"Defective mineralization in X-linked hypophosphatemia dental pulp cell cultures","volume":"97","author":"Coyac","year":"2018","journal-title":"J Dent Res"},{"key":"2025120619125041000_10.6.e036367.35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5395\/rde.2017.42.2.146","article-title":"Dental management of patients with X-linked hypophosphatemia","volume":"42","author":"Lee","year":"2017","journal-title":"Restor Dent Endod"},{"key":"2025120619125041000_10.6.e036367.36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","article-title":"X-linked hypophosphatemia: management and treatment prospects","volume":"86","author":"Lambert","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2025120619125041000_10.6.e036367.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.12.052"},{"key":"2025120619125041000_10.6.e036367.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2009.06.015"},{"key":"2025120619125041000_10.6.e036367.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.011"},{"key":"2025120619125041000_10.6.e036367.40","article-title":"Development, validation, and norming of the SF-10 for children health survey (abstract)","volume":"15","author":"Saris-Baglama","year":"2006","journal-title":"Qual Life Res"},{"key":"2025120619125041000_10.6.e036367.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00314-1"},{"key":"2025120619125041000_10.6.e036367.42","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2025120619125041000_10.6.e036367.43","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"2025120619125041000_10.6.e036367.44","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90143-4"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-036367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:13:03Z","timestamp":1765077183000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-036367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,29]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/bmjopen-2019-036367"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-036367","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}